Navigation Links
Wayne State vision restoration technology receives Notice of Allowance for US patent app
Date:3/5/2013

DETROIT Technology to restore vision through the use of a component of green algae developed by Dr. Zhou-Han Pan, professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute at Wayne State University, and licensed to RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574). The notice broadly covers methods of restoring visual responses with a variety of optogenetic compounds.

The application includes claims covering methods of restoring visual responses by delivery to retinal neurons any of a number of channelrhodopsin variants, as well as halorhodopsin. The two molecules have been studied extensively and published on as means of vision restoration in retinal degenerative conditions such as retinitis pigmentosa and dry age-related macular degeneration.

The approved patent application is part of the "Pan" patent family, which stems from the novel research of Pan and others at Wayne State University and Salus University, designed to restore vision in retinal degenerative conditions. Several Pan patent applications are part of RetroSense's intellectual property estate, which focuses on optogenetic gene therapies and complementary devices for vision restoration.

"We are pleased that the U.S. Patent Office has allowed this patent application, which will substantively expand the coverage of RetroSense's intellectual property estate," said Sean Ainsworth, chief executive officer of RetroSense. "Our IP position provides broad protection. RetroSense continues to develop novel intellectual property in the area of optogenetics. Accordingly, we plan to continue to extend our basic patent protections on our technologies. We have also maintained an ongoing strategy to consolidate key intellectual property required to develop and commercialize optogenetics to restore visual responses."

The newly allowed U.S. patent application covers methods of increasing visually evoked potentials by delivering to retinal neurons one or more of the following molecules:

  • Channelrhodopsin-2 (and a multitude of variants thereof)
  • Halorhodopsin

Claims also explicitly cover targeting these molecules with cell-type specific promoters, including mGluR6 (Grm6).

Following a Notice of Allowance, the process resulting in final issuance of a patent involves several administrative steps that are typically completed within a year.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related biology news :

1. Wayne State study shows airborne dust in urban areas impacts lead levels in children
2. Wayne State University researchers techniques enable more, faster testing of biological liquids
3. Cancer risk for African-American women with benign breast disease factors Wayne State finds
4. High-strength material advancements at Wayne State University may lead to new, life-saving steel
5. New book on physics principles by Wayne State professor explains life as we know it
6. Wayne State receives $2.8 million grant from US Administration for Children and Families
7. Wayne State researchers working to improve genetic analysis, disorder detection
8. Wayne State University researchers program targets safer river fishing, anglers health
9. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
10. Iowa State computer, electrical engineers working to help biologists cope with big data
11. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... Coral Springs, FL (PRWEB) , ... July 26, ... ... today announced that the stock market news outlet had initiated coverage on Aytu ... an established and producing commercialization strategy. , According to Soulstring, Aytu Bioscience is ...
(Date:7/26/2017)... /PRNewswire/ - Caprion Biosciences Inc., a world leading specialty CRO announced ... predictive of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using ... (MRM-MS) platform. ... Caprion Biosciences Inc. (CNW Group/Caprion Biosciences) ... The new data, recently published in ...
(Date:7/26/2017)... ... July 25, 2017 , ... Provia ... are necessary in the preparation and development of human cells and tissues for ... the US Food and Drug Administration’s (FDA) Current Good Manufacturing Practices (cGMP) guidelines ...
(Date:7/26/2017)... , July 26, 2017  Nurse practitioners play a ... the findings of a Merck Manuals survey released ... medical conference, revealed that most (88 percent) believe they spend ... treatments and prescriptions. ... Merck Manuals survey of 210 nurse ...
Breaking Biology Technology: